These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Coaxially electrospun fiber-based microbicides facilitate broadly tunable release of maraviroc. Ball C; Chou SF; Jiang Y; Woodrow KA Mater Sci Eng C Mater Biol Appl; 2016 Jun; 63():117-24. PubMed ID: 27040202 [TBL] [Abstract][Full Text] [Related]
4. A topical microbicide gel formulation of CCR5 antagonist maraviroc prevents HIV-1 vaginal transmission in humanized RAG-hu mice. Neff CP; Kurisu T; Ndolo T; Fox K; Akkina R PLoS One; 2011; 6(6):e20209. PubMed ID: 21673796 [TBL] [Abstract][Full Text] [Related]
5. Non-aqueous silicone elastomer gels as a vaginal microbicide delivery system for the HIV-1 entry inhibitor maraviroc. Forbes CJ; Lowry D; Geer L; Veazey RS; Shattock RJ; Klasse PJ; Mitchnick M; Goldman L; Doyle LA; Muldoon BC; Woolfson AD; Moore JP; Malcolm RK J Control Release; 2011 Dec; 156(2):161-9. PubMed ID: 21864598 [TBL] [Abstract][Full Text] [Related]
6. Pharmacodynamic Activity of Dapivirine and Maraviroc Single Entity and Combination Topical Gels for HIV-1 Prevention. Dezzutti CS; Yandura S; Wang L; Moncla B; Teeple EA; Devlin B; Nuttall J; Brown ER; Rohan LC Pharm Res; 2015 Nov; 32(11):3768-81. PubMed ID: 26078001 [TBL] [Abstract][Full Text] [Related]
7. Development and characterization of a solid dispersion film for the vaginal application of the anti-HIV microbicide UAMC01398. Grammen C; Van den Mooter G; Appeltans B; Michiels J; Crucitti T; Ariën KK; Augustyns K; Augustijns P; Brouwers J Int J Pharm; 2014 Nov; 475(1-2):238-44. PubMed ID: 25175729 [TBL] [Abstract][Full Text] [Related]
8. Advances in development, scale-up and manufacturing of microbicide gels, films, and tablets. Garg S; Goldman D; Krumme M; Rohan LC; Smoot S; Friend DR Antiviral Res; 2010 Dec; 88 Suppl 1():S19-29. PubMed ID: 21109064 [TBL] [Abstract][Full Text] [Related]
9. Electrospun fibers for vaginal anti-HIV drug delivery. Blakney AK; Ball C; Krogstad EA; Woodrow KA Antiviral Res; 2013 Dec; 100 Suppl():S9-16. PubMed ID: 24188701 [TBL] [Abstract][Full Text] [Related]
10. Measurement of anti-HIV activity of marketed vaginal products and excipients using a PBMC-based in vitro assay. Rohan LC; Ratner D; McCullough K; Hiller SL; Gupta P Sex Transm Dis; 2004 Mar; 31(3):143-8. PubMed ID: 15076925 [TBL] [Abstract][Full Text] [Related]
11. Biophysical characterization of small molecule antiviral-loaded nanolipogels for HIV-1 chemoprophylaxis and topical mucosal application. Ramanathan R; Jiang Y; Read B; Golan-Paz S; Woodrow KA Acta Biomater; 2016 May; 36():122-31. PubMed ID: 26947382 [TBL] [Abstract][Full Text] [Related]
12. Manufacturing scale-up of electrospun poly(vinyl alcohol) fibers containing tenofovir for vaginal drug delivery. Krogstad EA; Woodrow KA Int J Pharm; 2014 Nov; 475(1-2):282-91. PubMed ID: 25169075 [TBL] [Abstract][Full Text] [Related]
13. Formulation, pharmacokinetics and pharmacodynamics of topical microbicides. Adams JL; Kashuba AD Best Pract Res Clin Obstet Gynaecol; 2012 Aug; 26(4):451-62. PubMed ID: 22306523 [TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics and efficacy of a vaginally administered maraviroc gel in rhesus macaques. Malcolm RK; Forbes CJ; Geer L; Veazey RS; Goldman L; Klasse PJ; Moore JP J Antimicrob Chemother; 2013 Mar; 68(3):678-83. PubMed ID: 23111849 [TBL] [Abstract][Full Text] [Related]
15. Macaque studies of vaccine and microbicide combinations for preventing HIV-1 sexual transmission. Barouch DH; Klasse PJ; Dufour J; Veazey RS; Moore JP Proc Natl Acad Sci U S A; 2012 May; 109(22):8694-8. PubMed ID: 22586094 [TBL] [Abstract][Full Text] [Related]
16. SHIV-162P3 infection of rhesus macaques given maraviroc gel vaginally does not involve resistant viruses. Tsibris AM; Pal U; Schure AL; Veazey RS; Kunstman KJ; Henrich TJ; Klasse PJ; Wolinsky SM; Kuritzkes DR; Moore JP PLoS One; 2011; 6(12):e28047. PubMed ID: 22164225 [TBL] [Abstract][Full Text] [Related]
17. Biocompatibility of solid-dosage forms of anti-human immunodeficiency virus type 1 microbicides with the human cervicovaginal mucosa modeled ex vivo. Trifonova RT; Pasicznyk JM; Fichorova RN Antimicrob Agents Chemother; 2006 Dec; 50(12):4005-10. PubMed ID: 17030562 [TBL] [Abstract][Full Text] [Related]
18. Semi-solid gels function as physical barriers to human immunodeficiency virus transport in vitro. Lai BE; Geonnotti AR; Desoto MG; Montefiori DC; Katz DF Antiviral Res; 2010 Nov; 88(2):143-51. PubMed ID: 20709109 [TBL] [Abstract][Full Text] [Related]
19. Microbicides may be ready. AIDS Patient Care STDS; 2002 May; 16(5):243. PubMed ID: 12055033 [No Abstract] [Full Text] [Related]
20. Role of Semen on Vaginal HIV-1 Transmission and Maraviroc Protection. Council OD; Swanson MD; Spagnuolo RA; Wahl A; Garcia JV Antimicrob Agents Chemother; 2015 Dec; 59(12):7847-51. PubMed ID: 26392489 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]